spartalizumab + LAG525 + NIR178 + capmatinib + MCS110 + canakinumab
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer (TNBC)
Conditions
Triple Negative Breast Cancer (TNBC)
Trial Timeline
Jan 31, 2019 → Feb 6, 2023
NCT ID
NCT03742349About spartalizumab + LAG525 + NIR178 + capmatinib + MCS110 + canakinumab
spartalizumab + LAG525 + NIR178 + capmatinib + MCS110 + canakinumab is a phase 1 stage product being developed by Novartis for Triple Negative Breast Cancer (TNBC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03742349. Target conditions include Triple Negative Breast Cancer (TNBC).
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer (TNBC) were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03742349 | Phase 1 | Terminated |
Competing Products
20 competing products in Triple Negative Breast Cancer (TNBC)